Loading...
Docoh

Biolife Solutions (BLFS)

Document And Entity Information

Document And Entity Information - shares3 Months Ended
Mar. 31, 2022May 06, 2022
Document Information [Line Items]
Entity Central Index Key0000834365
Entity Registrant NameBIOLIFE SOLUTIONS INC
Amendment Flagfalse
Current Fiscal Year End Date--12-31
Document Fiscal Period FocusQ1
Document Fiscal Year Focus2022
Document Type10-Q
Document Quarterly Reporttrue
Document Period End DateMar. 31,
2022
Document Transition Reportfalse
Entity File Number001-36362
Entity Incorporation, State or Country CodeDE
Entity Tax Identification Number94-3076866
Entity Address, Address Line One3303 Monte Villa Parkway, Suite 310
Entity Address, City or TownBothell
Entity Address, State or ProvinceWA
Entity Address, Postal Zip Code98021
City Area Code425
Local Phone Number402-1400
Title of 12(b) SecurityBioLife Solutions, Inc. Common Shares
Trading SymbolBLFS
Security Exchange NameNASDAQ
Entity Current Reporting StatusYes
Entity Interactive Data CurrentYes
Entity Filer CategoryLarge Accelerated Filer
Entity Small Businessfalse
Entity Emerging Growth Companyfalse
Entity Shell Companyfalse
Entity Common Stock, Shares Outstanding42,409,719

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in ThousandsMar. 31, 2022Dec. 31, 2021
Current assets:
Cash and cash equivalents $ 59,463 $ 69,860
Restricted cash10 10
Accounts receivable, trade, net of allowance for doubtful accounts of $275 and $275 as of March 31, 2022 and December 31, 2021, respectively24,271 23,217
Inventories, net30,200 28,345
Prepaid expenses and other current assets4,757 4,427
Total current assets118,701 125,859
Assets held for rent, net9,823 9,809
Property and equipment, net18,259 17,657
Operating lease right-of-use assets, net18,161 18,705
Financing lease right-of-use assets, net404 440
Long-term deposits and other assets265 325
Investments4,372 4,372
Total intangible assets, net149,286 152,149
Goodwill224,741 224,741
Total assets544,012 554,057
Current liabilities:
Accounts payable11,711 14,945
Accrued expenses and other current liabilities6,966 7,142
Warranty liability9,176 9,398
Lease liabilities, operating, current portion2,795 2,758
Lease liabilities, financing, current portion151 149
Debt, current portion557 862
Contingent consideration, current portion3,684 5,127
Total current liabilities35,040 40,381
Contingent consideration, long-term3,008 4,900
Lease liabilities, operating, long-term15,917 16,466
Lease liabilities, financing, long-term253 291
Total long-term debt6,313 6,353
Deferred tax liabilities4,888 5,487
Other long-term liabilities73 42
Total liabilities65,492 73,920
Commitments and Contingencies (Note 12)
Shareholders’ equity:
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of March 31, 2022 and December 31, 20210 0
Common stock, $0.001 par value; 150,000,000 shares authorized, 42,331,082 and 41,817,503 shares issued and outstanding, respectively, as of March 31, 2022 and December 31, 202142 42
Additional paid-in capital591,002 585,397
Accumulated other comprehensive loss, net of taxes(438)(282)
Accumulated deficit(112,086)(105,020)
Total shareholders’ equity478,520 480,137
Total liabilities and shareholders’ equity $ 544,012 $ 554,057

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Balance Sheets (Parentheticals) - USD ($) $ in ThousandsMar. 31, 2022Dec. 31, 2021
Accounts receivable, allowance for doubtful accounts $ 275 $ 275
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares)1,000,000 1,000,000
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, authorized (in shares)150,000,000 150,000,000
Common stock, issued (in shares)42,331,082 41,817,503
Common stock, outstanding (in shares)42,331,082 41,817,503
Series A Preferred Stock [Member]
Preferred stock, shares designated (in shares)4,250 4,250
Preferred stock, issued (in shares)0 0
Preferred stock, outstanding (in shares)0 0

Unaudited Condensed Consolida_3

Unaudited Condensed Consolidated Statements of Operations - USD ($)3 Months Ended
Mar. 31, 2022Mar. 31, 2021
Revenue $ 36,220,000 $ 16,847,000
Costs and operating expenses:
Research and development3,781,000 1,987,000
Sales and marketing4,891,000 2,021,000
General and administrative11,196,000 4,830,000
Intangible asset amortization2,863,000 933,000
Acquisition costs11,000 998,000
Change in fair value of contingent consideration(3,335,000)(491,000)
Total operating expenses43,853,000 17,828,000
Operating loss(7,633,000)(981,000)
Other income (expense):
Change in fair value of warrant liability0 (121,000)
Interest expense, net(163,000)(16,000)
Other income131,000 0
Total other expense, net(32,000)(137,000)
Loss before income tax benefit(7,665,000)(1,118,000)
Income tax benefit599,000 0
Net loss(7,066,000)(1,118,000)
Net loss attributable to common shareholders:
Basic and Diluted $ (7,066,000) $ (1,118,000)
Basic and Diluted (in dollars per share) $ (0.17) $ (0.03)
Weighted average shares used to compute (loss) earnings per share attributable to common shareholders:
Basic and Diluted (in shares)42,014,055 33,236,818
Product [Member]
Revenue $ 30,388,000 $ 13,776,000
Costs and operating expenses:
Cost of goods and services20,384,000 5,622,000
Service Revenue [Member]
Revenue3,090,000 2,204,000
Costs and operating expenses:
Cost of goods and services2,145,000 1,353,000
Rental Revenue [Member]
Revenue2,742,000 867,000
Costs and operating expenses:
Cost of goods and services $ 1,917,000 $ 575,000

Unaudited Condensed Consolida_4

Unaudited Condensed Consolidated Statements of Comprehensive (Loss) Income - USD ($) $ in Thousands3 Months Ended
Mar. 31, 2022Mar. 31, 2021
Net loss $ (7,066) $ (1,118)
Other comprehensive loss - foreign currency translation adjustment, net of tax(156)0
Comprehensive loss $ (7,222) $ (1,118)

Unaudited Condensed Consolida_5

Unaudited Condensed Consolidated Statements of Shareholders' Equity - USD ($) $ in ThousandsPreferred Stock [Member]Series A Preferred Stock [Member]Common Stock [Member]Additional Paid-in Capital [Member]AOCI Attributable to Parent [Member]Retained Earnings [Member]Total
Balance at Dec. 31, 2020 $ 0 $ 33 $ 302,598 $ (97,385) $ 205,246
Balance (in shares) at Dec. 31, 20200 33,039,146
Stock-based compensation1,505 1,505
Stock option exercises (in shares)162,865
Stock option exercises $ 0 $ 0 243 $ 0 0 243
Stock issued – on vested RSAs (in shares)0 362,153
Stock issued – on vested RSAs $ 0 $ 0 0 0 0 0
Net loss0 0 0 0 (1,118)(1,118)
Cashless exercises of warrants0 $ 1 2,900 0 0 2,901
Cashless exercises of warrants (in shares)70,030
Balance (in shares) at Mar. 31, 202133,634,194
Balance at Mar. 31, 2021 $ 34 307,246 0 (98,503)208,777
Balance at Dec. 31, 2021 $ 0 $ 42 585,397 (282)(105,020)480,137
Balance (in shares) at Dec. 31, 202141,817,503
Stock-based compensation5,399 5,399
Stock option exercises (in shares)129,933
Stock option exercises257 0 0 257
Stock issued – on vested RSAs (in shares)0 383,646
Stock issued – on vested RSAs $ 0 $ 0 0 0 0 0
Fees incurred for registration filings(51)(51)
Foreign currency translation(156)(156)
Net loss $ 0 $ 0 0 0 (7,066)(7,066)
Balance (in shares) at Mar. 31, 202242,331,082
Balance at Mar. 31, 2022 $ 42 $ 591,002 $ (438) $ (112,086) $ 478,520

Unaudited Condensed Consolida_6

Unaudited Condensed Consolidated Statements of Shareholders' Equity (Parentheticals) - sharesMay 14, 2020Mar. 31, 2022Mar. 31, 2021
WAVI Holding AG and Taurus4757 GmbH Warrants [Member]
Cashless warrant exercises (in shares)3,871,405 79,100
Cashless warrant exercises (in shares)0 79,100

Unaudited Condensed Consolida_7

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)3 Months Ended
Mar. 31, 2022Mar. 31, 2021
Cash flows from operating activities
Net loss $ (7,066,000) $ (1,118,000)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities
Depreciation1,653,000 777,000
Amortization of intangible assets2,863,000 933,000
Stock-based compensation5,399,000 1,505,000
Non-cash lease expense524,000 410,000
Deferred income tax benefits(599,000)0
Change in fair value of contingent consideration(3,335,000)(491,000)
Change in fair value of warrant liability0 121,000
Loss on disposal of property and equipment, net18,000 0
(Gain) / loss on disposal of assets held for rent, net(96,000)65,000
Other(17,000)1,000
Change in operating assets and liabilities, net of effects of acquisitions
Accounts receivable, trade, net(1,083,000)(2,663,000)
Inventories(1,855,000)(65,000)
Prepaid expenses and other assets(25,000)52,000
Accounts payable(3,231,000)604,000
Accrued expenses and other current liabilities(1,074,000)1,689,000
Net cash (used in) provided by operating activities(7,924,000)1,820,000
Cash flows from investing activities
Purchases of property and equipment(1,456,000)(1,720,000)
Deposits on property and equipment0 (672,000)
Purchases of assets held for rent(814,000)(2,038,000)
Proceeds from sale of equipment0 3,000
Net cash used in investing activities(2,270,000)(4,427,000)
Cash flows from financing activities
Fees paid related to issuance of common stock(50,000)
Proceeds from exercise of common stock options257,000 243,000
Other42,000 (79,000)
Net cash (used in) provided by financing activities(181,000)1,216,000
Net decrease in cash, cash equivalents, and restricted cash(10,375,000)(1,391,000)
Cash, cash equivalents, and restricted cash – beginning of period69,870,000 90,456,000
Effects of currency translation on cash, cash equivalents, and restricted cash(22,000)0
Cash, cash equivalents, and restricted cash – end of period59,473,000 89,065,000
Non-cash investing and financing activities
Cashless exercise of warrants reclassified from warrant liability to common stock0 2,901,000
Equipment acquired under operating leases243,000 1,232,000
Equipment acquired under finance leases0 440,000
Purchase of property and equipment not yet paid13,000 0
Reclassification of property and equipment, net to assets held for rent, net0 27,000
Cash interest paid91,000 0
Equipment Loans [Member]
Cash flows from financing activities
Proceeds from Loan0 1,052,000
Payments on equipment loans(125,000)0
Financed Insurance Premium [Member]
Cash flows from financing activities
Payments on financed insurance premium $ (305,000) $ 0

Note 1 - Organization and Signi

Note 1 - Organization and Significant Accounting Policies3 Months Ended
Mar. 31, 2022
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]1. Business BioLife Solutions, Inc. (“BioLife”, “us”, “we”, “our”, or the “Company”) is a developer, manufacturer, and supplier of a portfolio of bioproduction tools and services including proprietary biopreservation media, automated cell processing fill machines, closed system cryogenic vials, human platelet lysate (“hPL”) growth media, automated thawing devices, cloud-connected shipping containers, ultra-low temperature mechanical freezers, cryogenic and controlled rate freezers and biological and pharmaceutical materials storage. Our CryoStor ® ® ® ® 20℃ 86℃. ® Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions by management affect the Company’s net realizable value of inventory, fair value of warrant liability, valuation of market based awards, valuations and purchase price allocations related to investments and business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, share-based compensation, contingent consideration from business combinations, and the recoverability of the Company’s deferred tax assets and the related valuation allowance. The Company regularly assesses these estimates; however, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Basis of presentation The Unaudited Condensed Consolidated Financial Statements included herein have been prepared by BioLife in accordance with U.S. GAAP and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), for Quarterly Reports on Form 10 10 X not 10 December 31, 2021. The Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries, SAVSU Technologies, Inc. (“SAVSU” acquired on August 8, 2019), November 12, 2019), October 1, 2020), May 3, 2021), September 1, 2021). In the opinion of management, the accompanying Unaudited Condensed Consolidated Financial Statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of the financial position, results of operations, and cash flows. The results of operations for the interim periods presented are not Foreign currency translation The Company translates items presented on its Unaudited Condensed Consolidated Balance Sheet and Unaudited Condensed Consolidated Statements of Operations into U.S. dollars. For the Company’s subsidiaries that operate in a local currency functional environment, all assets and liabilities are translated into U.S. dollars using current exchange rates at the balance sheet date; revenue and expenses are translated using average exchange rates in effect during each period. Resulting translation adjustments are reported as a separate component of Accumulated Other Comprehensive Loss in the Unaudited Condensed Consolidated Statements of Shareholders' Equity. Segment reporting The Company views its operations and makes decisions regarding how to allocate resources and manages its business as one one Significant accounting policies There have been no March 31, 2022, 10 Liquidity and capital resources On March 31, 2022 December 31, 2021, twelve 10 may may not Risks and uncertainties COVID- 19 Our domestic and international operations have been and continue to be affected by the ongoing global pandemic of a novel strain of coronavirus (“COVID- 19” In the three March 31, 2022 December 31, 2021, 19 not 19 19. The Company may 19 third Any disruption and volatility in the global capital markets as a result of the pandemic may 19 not The ultimate extent to which the COVID- 19 19 Concentrations of credit risk and business risk Significant customers are those that represent more than 10% Accounts Receivable Revenue March 31, December 31, March 31, 2022 2021 2022 2021 Customer A 16 % 10 % * * Customer B 14 % * 20 % * Customer C * * 11 % * * less than 10% Revenue from foreign customers is denominated in United States dollars or euros. The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Three Months Ended March 31, Revenue by customers geographic locations 2022 2021 United States 79 % 75 % Canada 1 % 10 % Europe, Middle East, Africa (EMEA) 16 % 12 % Other 4 % 3 % Total revenue 100 % 100 % In the three March 31, 2022 2021, no 10% As of March 31, 2022 2021 no 10% Recent accounting pronouncements In March 2022, No. 2022 02 Financial Instruments-Credit Losses (Topic 326 2022 02 2022 02 326 2022 02 December 15, 2022 2022 02

Note 2 - Fair Value Measurement

Note 2 - Fair Value Measurement3 Months Ended
Mar. 31, 2022
Notes to Financial Statements
Fair Value Disclosures [Text Block]2. Fair value measurement In accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures 820” 2 820 820 three Level 1 Level 2 1 not Level 3 The fair value of the CBS Contingent Consideration Liability was initially valued based on unobservable inputs using a Monte Carlo simulation. These inputs included the estimated amount and timing of projected future revenue, a discount rate of 26.0%, a risk-free rate of approximately 1.74% and revenue volatility of 70%. Significant increases (decreases) in any of those inputs in isolation would result in a significantly higher (lower) fair value measurement. Generally, changes used in the assumptions for projected future revenue and revenue volatility would be accompanied by a directionally similar change in the fair value measurement. Conversely, changes in the discount rate would be accompanied by a directionally opposite change in the related fair value measurement. However, due to the contingent consideration having a maximum payout amount, changes in these assumptions would not December 31, 2021, March 31, 2022 December 31, 2021 The fair value of the SciSafe Contingent Consideration Liability was initially valued based on unobservable inputs using a Monte Carlo simulation. These inputs included the estimated amount and timing of projected future revenue, a discount rate of 4.5%, a risk-free rate of approximately 0.20%, asset volatility of 60%, and revenue volatility of 15%. Significant increases (decreases) in any of those inputs in isolation would result in a significantly higher (lower) fair value measurement. Generally, changes used in the assumptions for projected future revenue and revenue volatility would be accompanied by a directionally similar change in the fair value measurement. Conversely, changes in the discount rate would be accompanied by a directionally opposite change in the related fair value measurement. However, due to the contingent consideration having a maximum payout amount, changes in these assumptions would not March 31, 2022, March 31, 2022 December 31, 2021 three March 31, 2022 2021, For the warrant liability, the significant Level 3 March 25, 2021. There were no three March 31, 2022 not The following tables set forth the Company’s financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2022 December 31, 2021, three (In thousands) As of March 31, 2022 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 52,380 $ - $ - $ 52,380 Total 52,380 - - 52,380 Liabilities: Contingent consideration - business combinations - - 6,692 6,692 Debt - 6,870 - 6,870 Total $ - $ 6,870 $ 6,692 $ 13,562 As of December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 63,873 $ - $ - $ 63,873 Total 63,873 - - 63,873 Liabilities: Contingent consideration - business combinations - - 10,027 10,027 Debt - 7,215 - 7,215 Total $ - $ 7,215 $ 10,027 $ 17,242 The fair values of money market funds classified as Level 1 3 1 Organization and Significant Accounting Policies. no The following table presents the changes in fair value of contingent consideration liabilities which are measured using Level 3 Three Months Ended March 31, (In thousands) 2022 2021 Beginning balance $ 10,027 $ 7,152 Change in fair value recognized in net loss (3,335 ) (491 ) Ending balance $ 6,692 $ 6,661 The following table presents the changes in fair value of warrant liabilities which are measured using Level 3 Three Months Ended March 31, (In thousands) 2022 2021 Beginning balance $ - $ 2,780 Exercised warrants - (2,901 ) Change in fair value recognized in net loss - 121 Ending balance $ - $ -

Note 3 - Acquisitions

Note 3 - Acquisitions3 Months Ended
Mar. 31, 2022
Notes to Financial Statements
Business Combination Disclosure [Text Block]3. Sexton acquisition General terms and effects On August 9, 2021, On September 1, 2021, Total consideration transferred (in thousands, except number of shares and stock price): Merger consideration shares 530,502 BioLife stock price (as of September 1, 2021) $ 60.50 Value of issued shares $ 32,095 plus: Fair value of BioLife’s existing investment in Sexton $ 7,951 less: Net working capital adjustment $ (118 ) Merger Consideration $ 39,928 Transaction costs related to the acquisition are expensed as incurred and are not Fair value of net assets acquired Under the acquisition method of accounting, the assets acquired and liabilities assumed from Sexton were calculated as of the merger date, at their respective fair values, and consolidated with those of BioLife. The gross contractual accounts receivable acquired in the acquisition was $509,000. Of the acquired accounts receivable, $17,000 is estimated to be uncollectable. The fair value calculations required critical estimates, including, but not The table below represents the fair value of the net assets acquired and liabilities assumed, which were recorded as of the merger date (amounts in thousands). Cash $ 1,516 Accounts receivable, net 492 Inventory 1,310 Prepaid expenses and other current assets 670 Property, plant and equipment, net 737 Operating lease right-of-use assets, net 470 Developed technology 4,132 Customer relationships 2,276 Tradenames 2,324 Non-compete agreements 90 Goodwill 28,470 Accounts payable (291 ) Lease liabilities, operating (470 ) Deferred tax liability (1,482 ) Other liabilities (316 ) Fair value of net assets acquired $ 39,928 We recorded a measurement period adjustment in the fourth December 31, 2021 The fair value of Sexton’s identifiable intangible assets and useful lives are as follows (amounts in thousands, except years): Fair Value Useful Life (Years) Developed technology $ 4,132 5 - 9 Customer relationships 2,276 2 Tradenames 2,324 11 Non-compete agreements 90 1 Total identifiable intangible assets $ 8,822 Fair value measurement methodologies used to calculate the value of any asset can be broadly classified into one three three not Some of the more significant assumptions inherent in the development of intangible asset fair values, from the perspective of a market participant, include, but are not Acquired goodwill The goodwill of $28.5 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. The goodwill recorded is not Global Cooling acquisition General terms and effects On March 19, 2021, On May 3, 2021, Merger consideration The aggregate merger consideration paid pursuant to the GCI Merger Agreement to the GCI Stockholders was 6,646,870 newly issued shares of common stock, provided, however, that the GCI Merger Consideration otherwise payable to GCI Stockholders is subject to the withholding of the GCI Escrow Shares (as defined below) and is subject to reduction for indemnification obligations. The GCI Merger Consideration allocable to one 805, not Total consideration transferred (in thousands, except number of shares, stock price, and consideration percentage): BioLife shares outstanding (as of March 19, 2021) 33,401,359 Merger consideration percentage 19.9 % Merger consideration shares 6,646,870 less: Merger consideration shares withheld to satisfy outstanding GCI stockholder obligations to GCI 10,400 Subtotal 6,636,470 BioLife stock price (as of May 3, 2021) $ 35.07 Value of issued shares $ 232,741 plus: Settlement of BioLife prepaid deposits $ 2,152 plus: Net settlement of BioLife accounts receivable $ 16 Merger Consideration $ 234,909 Transaction costs related to the acquisition are expensed as incurred and are not Escrow shares At the GCI Closing, approximately nine The GCI Escrow Property will be held for a period of up to twenty-four Fair value of net assets acquired Under the acquisition method of accounting, the assets acquired and liabilities assumed from Global Cooling were calculated as of the merger date, at their respective fair values, and consolidated with those of BioLife. The gross contractual accounts receivable acquired in the acquisition was $7.1 million. Of the acquired accounts receivable, $53,000 was estimated to be uncollectable. The fair value calculations required critical estimates, including, but not The table below represents the fair value of the net assets acquired and liabilities assumed, which were recorded as of the merger date (amounts in thousands). Cash $ 43 Accounts receivable, net 7,076 Inventory 15,547 Prepaid expenses and other current assets 639 Property, plant and equipment, net 3,512 Operating lease right-of-use assets, net 1,741 Financing lease right-of-use assets, net 114 Long-term deposits and other assets 4 Developed technology 18,140 Customer relationships 7,020 Tradenames 26,640 Non-compete agreements 1,240 In-process research and development 67,440 Goodwill 137,822 Accounts payable (9,837 ) Line of credit (4,231 ) Lease liabilities, operating (1,880 ) Lease liabilities, financing (114 ) Long-term debt (4,410 ) Deferred tax liability (24,133 ) Other liabilities (7,464 ) Fair value of net assets acquired $ 234,909 We recorded a measurement period adjustment in the fourth December 31, 2021 The fair value of Global Cooling’s identifiable intangible assets and useful lives are as follows (amounts in thousands, except years): Fair Value Useful Life (Years) Developed technology $ 18,140 6 Customer relationships 7,020 12 Tradenames 26,640 15 Non-compete agreements 1,240 4 In-process research and development 67,440 N/A Total identifiable intangible assets $ 120,480 Fair value measurement methodologies used to calculate the value of any asset can be broadly classified into one three three not Some of the more significant assumptions inherent in the development of intangible asset fair values, from the perspective of a market participant, include, but are not Acquired goodwill The goodwill of $137.8 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. The goodwill recorded is not Pro forma presentation The following unaudited pro forma financial information presents the combined results of operations of Sexton as if the acquisition had occurred on January 1, 2021 (In thousands) Three Months Ended March 31, 2021 (unaudited) Total revenue $ 17,855 Net (loss) income $ (1,924 ) The following unaudited pro forma financial information presents the combined results of operations of Global Cooling as if the acquisition had occurred on January 1, 2021 (In thousands) Three Months Ended March 31, 2021 (unaudited) Total revenue $ 34,949 Net income (loss) $ (10,562 )

Note 4 - Inventories

Note 4 - Inventories3 Months Ended
Mar. 31, 2022
Notes to Financial Statements
Inventory Disclosure [Text Block]4. Inventory consists of the following as of March 31, 2022 December 31, 2021: (In thousands) 2022 2021 Raw materials $ 16,634 $ 17,252 Work in progress 5,005 5,015 Finished goods 8,561 6,078 Total $ 30,200 $ 28,345

Note 5 - Assets Held for Rent

Note 5 - Assets Held for Rent3 Months Ended
Mar. 31, 2022
Notes to Financial Statements
Assets Held For Rent [Text Block]5. Assets held for rent Assets held for rent consist of the following as of March 31, 2022 December 31, 2021: (In thousands) 2022 2021 Shippers placed in service $ 6,032 $ 5,645 Fixed assets held for rent 4,686 4,040 Accumulated depreciation (3,070 ) (2,272 ) Net 7,648 7,413 Shippers and related components in production 2,175 2,396 Total $ 9,823 $ 9,809 Shippers and related components in production include shippers complete and ready to be deployed and placed in service upon a customer order, shippers in the process of being assembled, and components available to build shippers. We recognized $896,000 and $184,000 in depreciation expense related to assets held for rent during the three March 31, 2022 2021,

Note 6 - Goodwill and Intangibl

Note 6 - Goodwill and Intangible Assets3 Months Ended
Mar. 31, 2022
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]6. Goodwill Goodwill represents the difference between the purchase price and the estimated fair value of identifiable assets acquired and liabilities assumed. Goodwill acquired in a business combination is determined to have an indefinite useful life and is not 350. not three March 31, 2022. Intangible assets Intangible assets, net consisted of the following as of March 31, 2022 December 31, 2021: (In thousands, except weighted average useful life) March 31, 2022 Intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 17,516 $ (2,376 ) $ 15,140 10.1 Tradenames 35,574 (2,939 ) 32,635 13.6 Technology - acquired 41,942 (9,278 ) 32,664 5.6 Non-compete agreements 1,990 (583 ) 1,407 2.8 In-process research and development⁽¹⁾ 67,440 - 67,440 N/A Total intangible assets $ 164,462 $ (15,176 ) $ 149,286 9.6 (In thousands, except weighted average useful life) December 31, 2021 Intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 17,516 $ (1,776 ) $ 15,740 10.3 Tradenames 35,574 (2,306 ) 33,268 13.8 Technology - acquired 41,942 (7,789 ) 34,153 5.9 Non-compete agreements 1,990 (442 ) 1,548 3.0 In-process research and development⁽¹⁾ 67,440 - 67,440 N/A Total intangible assets $ 164,462 $ (12,313 ) $ 152,149 9.8 ( 1 Amortization expense for definite-lived intangible assets was $2.9 million and $933,000 for the three March 31, 2022 2021, March 31, 2022, (In thousands) Amortization For the Years Ending December 31, Expense 2022 (9 months remaining) $ 8,558 2023 10,951 2024 10,126 2025 9,748 2026 9,346 Thereafter 33,117 Total $ 81,846

Note 7 - Line of Credit and Lon

Note 7 - Line of Credit and Long-term Debt3 Months Ended
Mar. 31, 2022
Notes to Financial Statements
Long-Term Debt [Text Block]7. Long-term debt consisted of the following as of March 31, 2022 December 31, 2021: (In thousands) Maturity Date Interest Rate March 31, 2022 December 31, 2021 2022 term loan 1 Sep-24 4.0 % $ 1,750 $ 1,750 2022 term loan 2 Various 4.0 % 2,896 2,813 Insurance premium financing Apr-22 4.0 % 69 373 Freezer equipment loan Dec-25 5.7 % 572 612 Manufacturing equipment loans Oct-25 5.7 % 333 355 Freezer installation loan Various 6.3 % 1,271 1,334 Other loans Various Various 8 9 Total debt, excluding unamortized debt issuance costs 6,899 7,246 Less: unamortized debt issuance costs (29 ) (31 ) Total debt 6,870 7,215 Less: current portion (557 ) (862 ) Total long-term debt $ 6,313 $ 6,353 The 2022 As of March 31, 2022, five (In thousands) Amount 2022 (9 months remaining) $ 432 2023 813 2024 2,294 2025 543 2026 221 Thereafter 2,596 Total debt, excluding unamortized debt issuance costs 6,899 Less: unamortized debt issuance costs (29 ) Total debt $ 6,870

Note 8 - Stock-based Compensati

Note 8 - Stock-based Compensation3 Months Ended
Mar. 31, 2022
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]8. Share-based compensation Service vesting-based stock options The following is a summary of service vesting-based stock option activity for the three March 31, 2022, March 31, 2022: Three Months Ended March 31, 2022 Shares Wtd. Avg. Exercise Price Outstanding as of beginning of year 624,531 $ 2.13 Exercised (129,933 ) 1.98 Outstanding as of March 31, 2022 494,598 $ 2.17 Stock options exercisable as of March 31, 2022 494,598 $ 2.17 We recognized stock compensation expense related to service-based options of zero three March 31, 2022 2021. March 31, 2022, March 31, 2022. three March 31, 2022 2021 three March 31, 2022 2021. March 31, 2022 March 31, 2022. Performance-based stock options No three March 31, 2022 2021 three March 31, 2022 2021 three March 31, 2022 2021. Restricted stock Service vesting-based restricted stock The following is a summary of service vesting-based restricted stock activity for the three March 31, 2022, March 31, 2022: Three Months Ended March 31, 2022 Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year 1,212,783 $ 37.48 Granted 301,011 26.38 Vested (165,366 ) 37.48 Forfeited (14,642 ) 44.37 Non-vested as of March 31, 2022 1,333,786 $ 34.90 The aggregate fair value of the service vesting-based awards granted during the three March 31, 2022 2021 three March 31, 2022 2021 We recognized stock compensation expense of $4.8 million and $1.4 million related to service vesting-based awards during the three March 31, 2022 2021, March 31, 2022, Market-based restricted stock The following is a summary of market-based restricted stock activity under our stock option plan for the three March 31, 2022 March 31, 2022: Three Months Ended March 31, 2022 Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year 139,756 $ 19.86 Granted 349,568 22.66 Vested (218,280 ) 10.95 Non-vested as of March 31, 2022 271,044 $ 30.64 On March 25, 2020, February 24, 2022, January 1, 2020 December 31, 2021 20 0% 2 December 31, 2021. On February 8, 2021, January 1, 2021 December 31, 2022 20 0% December 31, 2022. On February 24, 2022, January 1, 2022 December 31, 2023 20 0% December 31, 2023. We recognized stock compensation expense of $605,000 and $285,000 related to market-based restricted stock awards for the three March 31, 2022 2021. March 31, 2022, The aggregate fair value of the market-based awards granted during the three March 31, 2022 2021 three March 31, 2022 2021 Total stock compensation expense We recorded total stock compensation expense for the three March 31, 2022 2021, Three Months Ended March 31, 2022 2021 Research and development costs $ 677 $ 183 Sales and marketing costs 705 184 General and administrative costs 3,010 979 Cost of revenue 1,007 159 Total $ 5,399 $ 1,505

Note 9 - Warrants

Note 9 - Warrants3 Months Ended
Mar. 31, 2022
Notes to Financial Statements
Warrants [Text Block]9. In March 2014, March 2021. In May 2016, May 2021. In May 2020, Taurus4757 In March 2021, The following table summarizes warrant activity for the three March 31, 2022 2021: Three Months Ended March 31, 2022 2021 Shares Wtd. Avg. Exercise Price Shares Wtd. Avg. Exercise Price Beginning balance - $ - 79,100 $ 4.75 Exercised - - (79,100 ) 4.75 Ending balance - $ - - $ -

Note 10 - Income Taxes

Note 10 - Income Taxes3 Months Ended
Mar. 31, 2022
Notes to Financial Statements
Income Tax Disclosure [Text Block]10. The Company accounts for income taxes under ASC Topic 740 The Company’s tax provision for interim periods is determined using an estimate of the annual effective income tax rate, adjusted for discrete items, if any, that occur in the relevant period. The income tax benefit of $599,000 for the three March 31, 2022 The Company’s US projected effective income tax rate without discrete items was 5%, which is lower than the US federal statutory rate of 21% primarily due to the impact of a projected partial valuation allowance on net operating loss carryforwards and non-deductible executive compensation offset by state tax benefits and research tax credits. Realization of deferred tax assets is dependent upon the generation of future taxable income, the timing and amount of which are uncertain. In determining the need for a valuation allowance, the Company’s management evaluates both positive and negative evidence when concluding whether it is more likely than not

Note 11 - Net (Loss) Income Per

Note 11 - Net (Loss) Income Per Common Share3 Months Ended
Mar. 31, 2022
Notes to Financial Statements
Earnings Per Share [Text Block]11. The Company considers its unexercised warrants and unvested restricted shares, which contain non-forfeitable rights to dividends, participating securities, and includes such participating securities in its computation of earnings per share pursuant to the two two two The following table presents computations of basic and diluted earnings per share under the two Three Months Ended March 31, (In thousands, except share and earnings per share data) 2022 2021 Numerator: Net loss $ (7,066 ) $ (1,118 ) Less: Preferred stock dividends and accumulated deficit impact of preferred stock redemption - - Basic net loss attributable to common stockholders (7,066 ) (1,118 ) Denominator: Basic and diluted weighted averge shares outstanding 42,014,055 33,236,818 Basic and diluted earnings per share attributable to common stockholders $ (0.17 ) $ (0.03 ) The following table sets forth the number of weighted-average common shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: Three Months Ended March 31, 2022 2021 Stock options and restricted stock awards 2,094,863 2,134,884 Warrants - 73,827 Total 2,094,863 2,208,711

Note 12 - Commitments and Conti

Note 12 - Commitments and Contingencies3 Months Ended
Mar. 31, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]12. Employment agreements We have employment agreements with certain key employees. None may Litigation From time to time, the Company is subject to various legal proceedings that arise in the ordinary course of business, none may not Indemnification As permitted under Delaware law and in accordance with the Company’s bylaws, the Company is required to indemnify its officers and directors for certain errors and occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its directors. The Company believes the fair value of the indemnification rights and agreements is minimal. Accordingly, the Company has not March 31, 2022.

Note 13 - Revenue

Note 13 - Revenue3 Months Ended
Mar. 31, 2022
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]13. To determine revenue recognition for contractual arrangements that we determine are within the scope of Financial Accounting Standards Board (“FASB”) Topic 606, Revenue from Contracts with Customers five five may not 30 90 three March 31, 2022, The Company primarily recognizes product revenues, service revenues, and rental revenues. Product revenues are generated from the sale of cell processing tools, freezers, thawing devices, and cold chain products. We recognize product revenue, including shipping and handling charges billed to customers, at a point in time when we transfer control of our products to our customers, which is upon shipment for substantially all transactions. Shipping and handling costs are classified as part of cost of product revenue in the Consolidated Statement of Operations. Service revenues are generated from the storage of biological and pharmaceutical materials. We recognize service revenues over time as services are performed or ratably over the contract term. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount method, depending on the facts and circumstances relative to the contract. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph 606 10 32 18, not one None three March 31, 2022. The Company also generates revenue from the leasing of our property, plant, and equipment, operating right-of-use assets, and evo cold chain systems within its storage and cold chain services product line to customers pursuant to service contracts or rental arrangements entered into with the customer. Revenue from these arrangements is not 606 842, Lease The Company enters into various customer service agreements (collectively, “Service Contracts”) with customers to provide biological and pharmaceutical storage services. In certain of these Service Contracts, the property, plant, and equipment or operating right-of-use assets used to store the customer product are used only for the benefit of one may not The Company has assessed its Service Contracts and concluded that certain of the contracts for the storage of customer products met the criteria to be considered a leasing arrangement (“Embedded Leases”), with the Company as the lessor. The specific Service Contracts that met the criteria were those that provided a single customer with the ability to substantially direct the use of the Company’s property, plant, and equipment or operating right-of-use assets. Under ASC 842, None None Embedded Leases may Total bioproduction tools and services revenue for the three March 31, 2022 2021 Three Months Ended March 31, (In thousands, except percentages) 2022 2021 Product revenue Freezer and thaw $ 15,335 $ 4,848 Cell processing 14,899 8,928 Storage and cold chain services 154 - Service revenue Storage and cold chain services 3,090 2,204 Rental revenue Storage and cold chain services 2,742 867 Total revenue $ 36,220 $ 16,847 The following table includes estimated rental revenue expected to be recognized in the future related to embedded leases as well as estimated service revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting periods. The Company is electing not one 2014 09, Revenue from Contracts with Customers not one March 31, 2022. The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts: Year Ending December 31, (In thousands) 2022 (9 months remaining) 2023 2024 Total Rental revenue $ 7,068 $ 3,735 $ 900 $ 11,703 Service revenue $ 79 $ 116 $ 10 $ 205

Note 14 - Leases

Note 14 - Leases3 Months Ended
Mar. 31, 2022
Notes to Financial Statements
Lessee, Leases [Text Block]14. We have various operating lease agreements for office space, warehouses, manufacturing, and production locations as well as vehicles and other equipment. Our real estate leases have remaining lease terms of one ten not one five one five Our financing leases relate to research equipment, machinery, and other equipment. The table below presents certain information related to the weighted average discount rate and weighted average remaining lease term for the Company’s leases as of March 31, 2022 December 31, 2021: March 31, December 31, (In thousands) 2022 2021 Weighted average discount rate - operating leases 3.8 % 3.8 % Weighted average discount rate - finance leases 6.1 % 6.1 % Weighted average remaining lease term in years - operating leases 7.6 7.8 Weighted average remaining lease term in years - finance leases 2.7 3.0 The components of lease expense for the three March 31, 2022 2021 Three Months Ended March 31, (In thousands) 2022 2021 Operating lease costs $ 913 $ 460 Short-term lease costs 565 137 Total operating lease costs 1,478 597 Variable lease costs 305 128 Total lease costs $ 1,783 $ 725 Maturities of our lease liabilities as of March 31, 2022 (In thousands) Operating Leases Financing Leases 2022 (9 months remaining) $ 2,626 $ 129 2023 3,230 171 2024 2,950 101 2025 2,485 37 2026 2,005 2 Thereafter 8,363 - Total lease payments 21,659 440 Less: interest (2,947 ) (36 ) Total present value of lease liabilities $ 18,712 $ 404

Note 15 - Consolidated Balance

Note 15 - Consolidated Balance Sheet Detail3 Months Ended
Mar. 31, 2022
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]15. Property and equipment (In thousands) March 31, 2022 December 31, 2021 Property and equipment Leasehold improvements $ 3,949 $ 3,840 Furniture and computer equipment 1,819 1,861 Manufacturing and other equipment 16,807 16,675 Construction in-progress 2,818 2,022 Subtotal 25,393 24,398 Less: Accumulated depreciation (7,134 ) (6,741 ) Net property and equipment $ 18,259 $ 17,657 Depreciation expense for property and equipment was $757,000 and $575,000 for the three March 31, 2022 2021, Accrued expenses and other current liabilities Accrued expenses and other current liabilities consist of the following: (In thousands) March 31, 2022 December 31, 2021 Accrued compensation $ 4,535 $ 4,351 Accrued expenses 1,372 1,656 Deferred revenue, current 895 814 Accrued taxes 33 27 Other 131 294 Total accrued expenses and other current liabilities $ 6,966 $ 7,142 Warranty reserve liability We reserve estimated exposures on known claims, as well as anticipated claims, for product warranty and rework cost, based on historical product liability claims. Claim costs are deducted from the accrual when paid. Factors that could have an impact on the warranty accrual in any given period include the following: changes in manufacturing quality, changes in product costs, changes in product mix and any significant changes in sales volume. A rollforward of our warranty liability is as follows: Three Months Ended March 31, (In thousands) 2022 2021 Beginning balance $ 9,398 $ 212 Provision for warranties 894 11 Settlements of warranty claims (1,116 ) (22 ) Ending Balance $ 9,176 $ 201

Note 16 - Employee Benefit Plan

Note 16 - Employee Benefit Plan3 Months Ended
Mar. 31, 2022
Notes to Financial Statements
Defined Contribution Plan [Text Block]16. The Company sponsors 401 may three March 31, 2022 2021,

Note 17 - Subsequent Events

Note 17 - Subsequent Events3 Months Ended
Mar. 31, 2022
Notes to Financial Statements
Subsequent Events [Text Block]17. The Company has evaluated events subsequent to March 31, 2022 no

Significant Accounting Policies

Significant Accounting Policies (Policies)3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions by management affect the Company’s net realizable value of inventory, fair value of warrant liability, valuation of market based awards, valuations and purchase price allocations related to investments and business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, share-based compensation, contingent consideration from business combinations, and the recoverability of the Company’s deferred tax assets and the related valuation allowance. The Company regularly assesses these estimates; however, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.
Basis of Accounting, Policy [Policy Text Block]Basis of presentation The Unaudited Condensed Consolidated Financial Statements included herein have been prepared by BioLife in accordance with U.S. GAAP and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), for Quarterly Reports on Form 10 10 X not 10 December 31, 2021. The Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries, SAVSU Technologies, Inc. (“SAVSU” acquired on August 8, 2019), November 12, 2019), October 1, 2020), May 3, 2021), September 1, 2021). In the opinion of management, the accompanying Unaudited Condensed Consolidated Financial Statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of the financial position, results of operations, and cash flows. The results of operations for the interim periods presented are not
Foreign Currency Transactions and Translations Policy [Policy Text Block]Foreign currency translation The Company translates items presented on its Unaudited Condensed Consolidated Balance Sheet and Unaudited Condensed Consolidated Statements of Operations into U.S. dollars. For the Company’s subsidiaries that operate in a local currency functional environment, all assets and liabilities are translated into U.S. dollars using current exchange rates at the balance sheet date; revenue and expenses are translated using average exchange rates in effect during each period. Resulting translation adjustments are reported as a separate component of Accumulated Other Comprehensive Loss in the Unaudited Condensed Consolidated Statements of Shareholders' Equity.
Segment Reporting, Policy [Policy Text Block]Segment reporting The Company views its operations and makes decisions regarding how to allocate resources and manages its business as one one
Liquidity and Capital Resources, Policy [Policy Text Block]Liquidity and capital resources On March 31, 2022 December 31, 2021, twelve 10 may may not
Risk and Uncertainties, Policy [Policy Text Block]Risks and uncertainties COVID- 19 Our domestic and international operations have been and continue to be affected by the ongoing global pandemic of a novel strain of coronavirus (“COVID- 19” In the three March 31, 2022 December 31, 2021, 19 not 19 19. The Company may 19 third Any disruption and volatility in the global capital markets as a result of the pandemic may 19 not The ultimate extent to which the COVID- 19 19
Concentration Risk, Credit Risk, Policy [Policy Text Block]Concentrations of credit risk and business risk Significant customers are those that represent more than 10% Accounts Receivable Revenue March 31, December 31, March 31, 2022 2021 2022 2021 Customer A 16 % 10 % * * Customer B 14 % * 20 % * Customer C * * 11 % * * less than 10% Revenue from foreign customers is denominated in United States dollars or euros. The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Three Months Ended March 31, Revenue by customers geographic locations 2022 2021 United States 79 % 75 % Canada 1 % 10 % Europe, Middle East, Africa (EMEA) 16 % 12 % Other 4 % 3 % Total revenue 100 % 100 % In the three March 31, 2022 2021, no 10% As of March 31, 2022 2021 no 10%
New Accounting Pronouncements, Policy [Policy Text Block]Recent accounting pronouncements In March 2022, No. 2022 02 Financial Instruments-Credit Losses (Topic 326 2022 02 2022 02 326 2022 02 December 15, 2022 2022 02

Note 1 - Organization and Sig_2

Note 1 - Organization and Significant Accounting Policies (Tables)3 Months Ended
Mar. 31, 2022
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]Accounts Receivable Revenue March 31, December 31, March 31, 2022 2021 2022 2021 Customer A 16 % 10 % * * Customer B 14 % * 20 % * Customer C * * 11 % *
Revenue from External Customers by Products and Services [Table Text Block]Three Months Ended March 31, Revenue by customers geographic locations 2022 2021 United States 79 % 75 % Canada 1 % 10 % Europe, Middle East, Africa (EMEA) 16 % 12 % Other 4 % 3 % Total revenue 100 % 100 %

Note 2 - Fair Value Measureme_2

Note 2 - Fair Value Measurement (Tables)3 Months Ended
Mar. 31, 2022
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]As of March 31, 2022 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 52,380 $ - $ - $ 52,380 Total 52,380 - - 52,380 Liabilities: Contingent consideration - business combinations - - 6,692 6,692 Debt - 6,870 - 6,870 Total $ - $ 6,870 $ 6,692 $ 13,562 As of December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 63,873 $ - $ - $ 63,873 Total 63,873 - - 63,873 Liabilities: Contingent consideration - business combinations - - 10,027 10,027 Debt - 7,215 - 7,215 Total $ - $ 7,215 $ 10,027 $ 17,242
Contingent Consideration Liabilities [Member]
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]Three Months Ended March 31, (In thousands) 2022 2021 Beginning balance $ 10,027 $ 7,152 Change in fair value recognized in net loss (3,335 ) (491 ) Ending balance $ 6,692 $ 6,661 Three Months Ended March 31, (In thousands) 2022 2021 Beginning balance $ - $ 2,780 Exercised warrants - (2,901 ) Change in fair value recognized in net loss - 121 Ending balance $ - $ -

Note 3 - Acquisitions (Tables)

Note 3 - Acquisitions (Tables)3 Months Ended
Mar. 31, 2022
Notes Tables
Schedule of Business Acquisitions, by Acquisition [Table Text Block]Merger consideration shares 530,502 BioLife stock price (as of September 1, 2021) $ 60.50 Value of issued shares $ 32,095 plus: Fair value of BioLife’s existing investment in Sexton $ 7,951 less: Net working capital adjustment $ (118 ) Merger Consideration $ 39,928 BioLife shares outstanding (as of March 19, 2021) 33,401,359 Merger consideration percentage 19.9 % Merger consideration shares 6,646,870 less: Merger consideration shares withheld to satisfy outstanding GCI stockholder obligations to GCI 10,400 Subtotal 6,636,470 BioLife stock price (as of May 3, 2021) $ 35.07 Value of issued shares $ 232,741 plus: Settlement of BioLife prepaid deposits $ 2,152 plus: Net settlement of BioLife accounts receivable $ 16 Merger Consideration $ 234,909
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]Cash $ 1,516 Accounts receivable, net 492 Inventory 1,310 Prepaid expenses and other current assets 670 Property, plant and equipment, net 737 Operating lease right-of-use assets, net 470 Developed technology 4,132 Customer relationships 2,276 Tradenames 2,324 Non-compete agreements 90 Goodwill 28,470 Accounts payable (291 ) Lease liabilities, operating (470 ) Deferred tax liability (1,482 ) Other liabilities (316 ) Fair value of net assets acquired $ 39,928 Cash $ 43 Accounts receivable, net 7,076 Inventory 15,547 Prepaid expenses and other current assets 639 Property, plant and equipment, net 3,512 Operating lease right-of-use assets, net 1,741 Financing lease right-of-use assets, net 114 Long-term deposits and other assets 4 Developed technology 18,140 Customer relationships 7,020 Tradenames 26,640 Non-compete agreements 1,240 In-process research and development 67,440 Goodwill 137,822 Accounts payable (9,837 ) Line of credit (4,231 ) Lease liabilities, operating (1,880 ) Lease liabilities, financing (114 ) Long-term debt (4,410 ) Deferred tax liability (24,133 ) Other liabilities (7,464 ) Fair value of net assets acquired $ 234,909
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]Fair Value Useful Life (Years) Developed technology $ 4,132 5 - 9 Customer relationships 2,276 2 Tradenames 2,324 11 Non-compete agreements 90 1 Total identifiable intangible assets $ 8,822 Fair Value Useful Life (Years) Developed technology $ 18,140 6 Customer relationships 7,020 12 Tradenames 26,640 15 Non-compete agreements 1,240 4 In-process research and development 67,440 N/A Total identifiable intangible assets $ 120,480
Business Acquisition, Pro Forma Information [Table Text Block](In thousands) Three Months Ended March 31, 2021 (unaudited) Total revenue $ 17,855 Net (loss) income $ (1,924 ) (In thousands) Three Months Ended March 31, 2021 (unaudited) Total revenue $ 34,949 Net income (loss) $ (10,562 )

Note 4 - Inventories (Tables)

Note 4 - Inventories (Tables)3 Months Ended
Mar. 31, 2022
Notes Tables
Schedule of Inventory, Current [Table Text Block](In thousands) 2022 2021 Raw materials $ 16,634 $ 17,252 Work in progress 5,005 5,015 Finished goods 8,561 6,078 Total $ 30,200 $ 28,345

Note 5 - Assets Held for Rent (

Note 5 - Assets Held for Rent (Tables)3 Months Ended
Mar. 31, 2022
Notes Tables
Scheduleof Assets Held for Rent [Table Text Block](In thousands) 2022 2021 Shippers placed in service $ 6,032 $ 5,645 Fixed assets held for rent 4,686 4,040 Accumulated depreciation (3,070 ) (2,272 ) Net 7,648 7,413 Shippers and related components in production 2,175 2,396 Total $ 9,823 $ 9,809

Note 6 - Goodwill and Intangi_2

Note 6 - Goodwill and Intangible Assets (Tables)3 Months Ended
Mar. 31, 2022
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block](In thousands, except weighted average useful life) March 31, 2022 Intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 17,516 $ (2,376 ) $ 15,140 10.1 Tradenames 35,574 (2,939 ) 32,635 13.6 Technology - acquired 41,942 (9,278 ) 32,664 5.6 Non-compete agreements 1,990 (583 ) 1,407 2.8 In-process research and development⁽¹⁾ 67,440 - 67,440 N/A Total intangible assets $ 164,462 $ (15,176 ) $ 149,286 9.6 (In thousands, except weighted average useful life) December 31, 2021 Intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 17,516 $ (1,776 ) $ 15,740 10.3 Tradenames 35,574 (2,306 ) 33,268 13.8 Technology - acquired 41,942 (7,789 ) 34,153 5.9 Non-compete agreements 1,990 (442 ) 1,548 3.0 In-process research and development⁽¹⁾ 67,440 - 67,440 N/A Total intangible assets $ 164,462 $ (12,313 ) $ 152,149 9.8
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block](In thousands) Amortization For the Years Ending December 31, Expense 2022 (9 months remaining) $ 8,558 2023 10,951 2024 10,126 2025 9,748 2026 9,346 Thereafter 33,117 Total $ 81,846

Note 7 - Line of Credit and L_2

Note 7 - Line of Credit and Long-term Debt (Tables)3 Months Ended
Mar. 31, 2022
Notes Tables
Schedule of Debt [Table Text Block](In thousands) Maturity Date Interest Rate March 31, 2022 December 31, 2021 2022 term loan 1 Sep-24 4.0 % $ 1,750 $ 1,750 2022 term loan 2 Various 4.0 % 2,896 2,813 Insurance premium financing Apr-22 4.0 % 69 373 Freezer equipment loan Dec-25 5.7 % 572 612 Manufacturing equipment loans Oct-25 5.7 % 333 355 Freezer installation loan Various 6.3 % 1,271 1,334 Other loans Various Various 8 9 Total debt, excluding unamortized debt issuance costs 6,899 7,246 Less: unamortized debt issuance costs (29 ) (31 ) Total debt 6,870 7,215 Less: current portion (557 ) (862 ) Total long-term debt $ 6,313 $ 6,353
Schedule of Maturities of Long-Term Debt [Table Text Block](In thousands) Amount 2022 (9 months remaining) $ 432 2023 813 2024 2,294 2025 543 2026 221 Thereafter 2,596 Total debt, excluding unamortized debt issuance costs 6,899 Less: unamortized debt issuance costs (29 ) Total debt $ 6,870

Note 8 - Stock-based Compensa_2

Note 8 - Stock-based Compensation (Tables)3 Months Ended
Mar. 31, 2022
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]Three Months Ended March 31, 2022 Shares Wtd. Avg. Exercise Price Outstanding as of beginning of year 624,531 $ 2.13 Exercised (129,933 ) 1.98 Outstanding as of March 31, 2022 494,598 $ 2.17 Stock options exercisable as of March 31, 2022 494,598 $ 2.17
Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]Three Months Ended March 31, 2022 Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year 1,212,783 $ 37.48 Granted 301,011 26.38 Vested (165,366 ) 37.48 Forfeited (14,642 ) 44.37 Non-vested as of March 31, 2022 1,333,786 $ 34.90 Three Months Ended March 31, 2022 Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year 139,756 $ 19.86 Granted 349,568 22.66 Vested (218,280 ) 10.95 Non-vested as of March 31, 2022 271,044 $ 30.64
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]Three Months Ended March 31, 2022 2021 Research and development costs $ 677 $ 183 Sales and marketing costs 705 184 General and administrative costs 3,010 979 Cost of revenue 1,007 159 Total $ 5,399 $ 1,505

Note 9 - Warrants (Tables)

Note 9 - Warrants (Tables)3 Months Ended
Mar. 31, 2022
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]Three Months Ended March 31, 2022 2021 Shares Wtd. Avg. Exercise Price Shares Wtd. Avg. Exercise Price Beginning balance - $ - 79,100 $ 4.75 Exercised - - (79,100 ) 4.75 Ending balance - $ - - $ -

Note 11 - Net (Loss) Income P_2

Note 11 - Net (Loss) Income Per Common Share (Tables)3 Months Ended
Mar. 31, 2022
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]Three Months Ended March 31, (In thousands, except share and earnings per share data) 2022 2021 Numerator: Net loss $ (7,066 ) $ (1,118 ) Less: Preferred stock dividends and accumulated deficit impact of preferred stock redemption - - Basic net loss attributable to common stockholders (7,066 ) (1,118 ) Denominator: Basic and diluted weighted averge shares outstanding 42,014,055 33,236,818 Basic and diluted earnings per share attributable to common stockholders $ (0.17 ) $ (0.03 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]Three Months Ended March 31, 2022 2021 Stock options and restricted stock awards 2,094,863 2,134,884 Warrants - 73,827 Total 2,094,863 2,208,711

Note 13 - Revenue (Tables)

Note 13 - Revenue (Tables)3 Months Ended
Mar. 31, 2022
Notes Tables
Revenues By Product Line [Table Text Block]Three Months Ended March 31, (In thousands, except percentages) 2022 2021 Product revenue Freezer and thaw $ 15,335 $ 4,848 Cell processing 14,899 8,928 Storage and cold chain services 154 - Service revenue Storage and cold chain services 3,090 2,204 Rental revenue Storage and cold chain services 2,742 867 Total revenue $ 36,220 $ 16,847
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]Year Ending December 31, (In thousands) 2022 (9 months remaining) 2023 2024 Total Rental revenue $ 7,068 $ 3,735 $ 900 $ 11,703 Service revenue $ 79 $ 116 $ 10 $ 205

Note 14 - Leases (Tables)

Note 14 - Leases (Tables)3 Months Ended
Mar. 31, 2022
Notes Tables
Lessee, Operating and Finance Lease Term And Discount Rate [Table Text Block]March 31, December 31, (In thousands) 2022 2021 Weighted average discount rate - operating leases 3.8 % 3.8 % Weighted average discount rate - finance leases 6.1 % 6.1 % Weighted average remaining lease term in years - operating leases 7.6 7.8 Weighted average remaining lease term in years - finance leases 2.7 3.0
Lease, Cost [Table Text Block]Three Months Ended March 31, (In thousands) 2022 2021 Operating lease costs $ 913 $ 460 Short-term lease costs 565 137 Total operating lease costs 1,478 597 Variable lease costs 305 128 Total lease costs $ 1,783 $ 725
Lessee, Operating Lease, Liability, Maturity [Table Text Block](In thousands) Operating Leases Financing Leases 2022 (9 months remaining) $ 2,626 $ 129 2023 3,230 171 2024 2,950 101 2025 2,485 37 2026 2,005 2 Thereafter 8,363 - Total lease payments 21,659 440 Less: interest (2,947 ) (36 ) Total present value of lease liabilities $ 18,712 $ 404

Note 15 - Consolidated Balanc_2

Note 15 - Consolidated Balance Sheet Detail (Tables)3 Months Ended
Mar. 31, 2022
Notes Tables
Property, Plant and Equipment [Table Text Block](In thousands) March 31, 2022 December 31, 2021 Property and equipment Leasehold improvements $ 3,949 $ 3,840 Furniture and computer equipment 1,819 1,861 Manufacturing and other equipment 16,807 16,675 Construction in-progress 2,818 2,022 Subtotal 25,393 24,398 Less: Accumulated depreciation (7,134 ) (6,741 ) Net property and equipment $ 18,259 $ 17,657
Schedule of Accrued Liabilities [Table Text Block](In thousands) March 31, 2022 December 31, 2021 Accrued compensation $ 4,535 $ 4,351 Accrued expenses 1,372 1,656 Deferred revenue, current 895 814 Accrued taxes 33 27 Other 131 294 Total accrued expenses and other current liabilities $ 6,966 $ 7,142
Schedule of Product Warranty Liability [Table Text Block]Three Months Ended March 31, (In thousands) 2022 2021 Beginning balance $ 9,398 $ 212 Provision for warranties 894 11 Settlements of warranty claims (1,116 ) (22 ) Ending Balance $ 9,176 $ 201

Note 1 - Organization and Sig_3

Note 1 - Organization and Significant Accounting Policies (Details Textual) - USD ($) $ in MillionsMar. 31, 2022Dec. 31, 2021
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Ending Balance $ 59.5 $ 69.9

Note 1 - Organization and Sig_4

Note 1 - Organization and Significant Accounting Policies - Significant Customers (Details) - Customer Concentration Risk [Member]3 Months Ended
Mar. 31, 2022Mar. 31, 2021
Accounts Receivable [Member] | Customer A [Member]
Customer A16.00%10.00%
Accounts Receivable [Member] | Customer B [Member]
Customer A14.00%
Revenue Benchmark [Member] | Customer B [Member]
Customer A20.00%
Revenue Benchmark [Member] | Customer C [Member]
Customer A11.00%

Note 1 - Organization and Sig_5

Note 1 - Organization and Significant Accounting Policies - Concentrations Risk by Geographic Locations (Details) - Revenue Benchmark [Member] - Geographic Concentration Risk [Member]3 Months Ended
Mar. 31, 2022Mar. 31, 2021
UNITED STATES
United States79.00%75.00%
CANADA
United States1.00%10.00%
EMEA [Member]
United States16.00%12.00%
Geographic, Other [Member]
United States4.00%3.00%
All Location [Member]
United States100.00%100.00%

Note 2 - Fair Value Measureme_3

Note 2 - Fair Value Measurement (Details Textual)3 Months Ended
Mar. 31, 2022USD ($)Mar. 31, 2021USD ($)Dec. 31, 2021USD ($)Oct. 01, 2020USD ($)Nov. 10, 2019
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability $ (3,335,000) $ (491,000)
CBS Acquisition [Member]
Business Combination, Contingent Consideration, Liability, Total $ 140,000
CBS Acquisition [Member] | Measurement Input, Discount Rate [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input0.210 0.260
CBS Acquisition [Member] | Measurement Input, Risk Free Interest Rate [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input0.0023 0.0174
CBS Acquisition [Member] | Measurement Input, Price Volatility [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input0.630.70
SciSafe Holdings, Inc [Member]
Business Combination, Contingent Consideration, Liability, Total6,600,000 $ 9,900,000 $ 3,700,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability $ 3,300,000 $ 491,000
SciSafe Holdings, Inc [Member] | Measurement Input, Discount Rate [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input9.9 0.045
SciSafe Holdings, Inc [Member] | Measurement Input, Risk Free Interest Rate [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input2.3 0.0020
SciSafe Holdings, Inc [Member] | Measurement Input, Asset Price Volatility [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input71 0.60
SciSafe Holdings, Inc [Member] | Measurement Input, Revenue Volatility [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input31 0.15

Note 2 - Fair Value Measureme_4

Note 2 - Fair Value Measurement - Financial Assets and Liabilities on Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in ThousandsMar. 31, 2022Dec. 31, 2021
Assets $ 52,380 $ 63,873
Liabilities13,562 17,242
Contingent Consideration Liabilities [Member]
Liabilities6,692
Long-Term Debt [Member]
Liabilities6,870 7,215
Money Market Funds [Member]
Assets52,380 63,873
Contingent Consideration Liabilities [Member]
Liabilities10,027
Fair Value, Inputs, Level 1 [Member]
Assets52,380 63,873
Liabilities0 0
Fair Value, Inputs, Level 1 [Member] | Contingent Consideration Liabilities [Member]
Liabilities0
Fair Value, Inputs, Level 1 [Member] | Long-Term Debt [Member]
Liabilities0 0
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Assets52,380 63,873
Fair Value, Inputs, Level 1 [Member] | Contingent Consideration Liabilities [Member]
Liabilities0
Fair Value, Inputs, Level 2 [Member]
Assets0 0
Liabilities6,870 7,215
Fair Value, Inputs, Level 2 [Member] | Contingent Consideration Liabilities [Member]
Liabilities0
Fair Value, Inputs, Level 2 [Member] | Long-Term Debt [Member]
Liabilities6,870 7,215
Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]
Assets0 0
Fair Value, Inputs, Level 2 [Member] | Contingent Consideration Liabilities [Member]
Liabilities0
Fair Value, Inputs, Level 3 [Member]
Assets0 0
Liabilities6,692 10,027
Fair Value, Inputs, Level 3 [Member] | Contingent Consideration Liabilities [Member]
Liabilities6,692
Fair Value, Inputs, Level 3 [Member] | Long-Term Debt [Member]
Liabilities0 0
Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]
Assets $ 0 0
Fair Value, Inputs, Level 3 [Member] | Contingent Consideration Liabilities [Member]
Liabilities $ 10,027

Note 2 - Fair Value Measureme_5

Note 2 - Fair Value Measurement - Fair Value of Contingent Consideration Using Level 3 Inputs (Details) - USD ($) $ in Thousands3 Months Ended
Mar. 31, 2022Mar. 31, 2021
Contingent Consideration Liabilities [Member]
Beginning balance $ 10,027 $ 7,152
Change in fair value recognized in net loss(3,335)(491)
Ending balance6,692 6,661
Warrant Liabilities [Member]
Beginning balance0 2,780
Change in fair value recognized in net loss0 121
Ending balance0 0
Exercised warrants $ 0 $ (2,901)

Note 3 - Acquisitions (Details

Note 3 - Acquisitions (Details Textual) - USD ($)Sep. 01, 2021May 03, 2021Dec. 31, 2021Mar. 31, 2022
Goodwill, Ending Balance $ 224,741,000 $ 224,741,000
Sexton Acquisition [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)530,502
Business Acquisition, Percentage of Equity Issuable Shares Held in Escrow Accounts for Post Closing Claims10.00%
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain (Loss), Net, Total $ 6,500,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Gross Receivables509,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Uncollectable Receivables17,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Previous Period198,000
Goodwill, Ending Balance $ 28,470,000
Sexton Acquisition [Member] | Common Stock Issued to Acquire Participating Holders [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)477,452
Sexton Acquisition [Member] | Common Stock Deposited Into Escrow [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)53,050
GCI Acquisition [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)6,636,470
Business Acquisition, Percentage of Equity Issuable Shares Held in Escrow Accounts for Post Closing Claims9.00%
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Gross Receivables $ 7,100,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Uncollectable Receivables53,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Previous Period $ 607,000
Goodwill, Ending Balance $ 137,822,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares, Before Adjustments (in shares)6,646,870
Business Combination, Stock Reduced During Period, Satisfy Note Receivable (in shares)10,400
Business Combination, Escrow Shares, Period (Month)24 months
GCI Acquisition [Member] | One GCI Stockholder [Member]
Business Combination, Stock Reduced During Period, Satisfy Note Receivable (in shares)10,400
Financing Receivable, after Allowance for Credit Loss, Total $ 374,000

Note 3 - Acquisitions - Conside

Note 3 - Acquisitions - Consideration (Details) - USD ($) $ / shares in Units, $ in ThousandsSep. 01, 2021May 03, 2021
BioLife stock price (in dollars per share) $ 60.50 $ 35.07
BioLife shares outstanding (as of March 19, 2021) (in shares)33,401,359
Sexton Acquisition [Member]
Merger consideration shares (in shares)530,502
Value of issued shares $ 32,095
plus: Fair value of BioLife’s existing investment in Sexton7,951
less: Net working capital adjustment(118)
Merger Consideration $ 39,928
GCI Acquisition [Member]
Merger consideration shares (in shares)6,636,470
Value of issued shares $ 232,741
Merger Consideration $ 234,909
Merger consideration percentage19.90%
Merger consideration shares (in shares)6,646,870
less: Merger consideration shares withheld to satisfy outstanding GCI stockholder obligations to GCI (in shares)10,400
plus: Settlement of BioLife prepaid deposits $ 2,152
plus: Net settlement of BioLife accounts receivable $ 16

Note 3 - Acquisitions - Fair Va

Note 3 - Acquisitions - Fair Value of Net Assets Acquired (Details) - USD ($) $ in ThousandsMar. 31, 2022Dec. 31, 2021Sep. 01, 2021May 03, 2021
Goodwill $ 224,741 $ 224,741
Sexton Acquisition [Member]
Cash $ 1,516
Accounts receivable, net492
Inventory1,310
Prepaid expenses and other current assets670
Property, plant and equipment, net737
Operating lease right-of-use assets, net470
Goodwill28,470
Accounts payable(291)
Lease liabilities, operating(470)
Deferred tax liability(1,482)
Other liabilities(316)
Fair value of net assets acquired39,928
Sexton Acquisition [Member] | Developed Technology Rights [Member]
Developed technology4,132
Sexton Acquisition [Member] | Customer Relationships [Member]
Developed technology2,276
Sexton Acquisition [Member] | Trade Names [Member]
Developed technology2,324
Sexton Acquisition [Member] | Noncompete Agreements [Member]
Developed technology $ 90
GCI Acquisition [Member]
Cash $ 43
Accounts receivable, net7,076
Inventory15,547
Prepaid expenses and other current assets639
Property, plant and equipment, net3,512
Operating lease right-of-use assets, net1,741
Goodwill137,822
Accounts payable(9,837)
Lease liabilities, operating(1,880)
Deferred tax liability(24,133)
Other liabilities(7,464)
Fair value of net assets acquired234,909
Financing lease right-of-use assets, net114
Long-term deposits and other assets4
Line of credit(4,231)
Lease liabilities, financing(114)
Long-term debt(4,410)
GCI Acquisition [Member] | Indefinite In Process Research and Development [Member]
In-process research and development67,440
GCI Acquisition [Member] | Developed Technology Rights [Member]
Developed technology18,140
GCI Acquisition [Member] | Customer Relationships [Member]
Developed technology7,020
GCI Acquisition [Member] | Trade Names [Member]
Developed technology26,640
GCI Acquisition [Member] | Noncompete Agreements [Member]
Developed technology $ 1,240

Note 3 - Acquisitions - Acquire

Note 3 - Acquisitions - Acquired Intangible Assets (Details) - USD ($) $ in ThousandsSep. 01, 2021May 03, 2021
Total identifiable intangible assets $ 8,822
Sexton Acquisition [Member] | Developed Technology Rights [Member]
Developed technology $ 4,132
Sexton Acquisition [Member] | Developed Technology Rights [Member] | Minimum [Member]
Intangible assets, estimated useful life (Year)5 years
Sexton Acquisition [Member] | Developed Technology Rights [Member] | Maximum [Member]
Intangible assets, estimated useful life (Year)9 years
Sexton Acquisition [Member] | Customer Relationships [Member]
Developed technology $ 2,276
Intangible assets, estimated useful life (Year)2 years
Sexton Acquisition [Member] | Trade Names [Member]
Developed technology $ 2,324
Intangible assets, estimated useful life (Year)11 years
Sexton Acquisition [Member] | Noncompete Agreements [Member]
Developed technology $ 90
Intangible assets, estimated useful life (Year)1 year
GCI Acquisition [Member]
Total identifiable intangible assets $ 120,480
GCI Acquisition [Member] | Indefinite In Process Research and Development [Member]
In-process research and development67,440
GCI Acquisition [Member] | Developed Technology Rights [Member]
Developed technology $ 18,140
Intangible assets, estimated useful life (Year)6 years
GCI Acquisition [Member] | Customer Relationships [Member]
Developed technology $ 7,020
Intangible assets, estimated useful life (Year)12 years
GCI Acquisition [Member] | Trade Names [Member]
Developed technology $ 26,640
Intangible assets, estimated useful life (Year)15 years
GCI Acquisition [Member] | Noncompete Agreements [Member]
Developed technology $ 1,240
Intangible assets, estimated useful life (Year)4 years

Note 3 - Acquisitions - Pro For

Note 3 - Acquisitions - Pro Forma Information (Details) $ in Thousands3 Months Ended
Mar. 31, 2021USD ($)
Sexton Acquisition [Member]
Total revenue $ 17,855
Net income (loss)(1,924)
GCI Acquisition [Member]
Total revenue34,949
Net income (loss) $ (10,562)

Note 4 - Inventories - Summary

Note 4 - Inventories - Summary of Inventories (Details) - USD ($) $ in ThousandsMar. 31, 2022Dec. 31, 2021
Raw materials $ 16,634 $ 17,252
Work in progress5,005 5,015
Finished goods8,561 6,078
Total $ 30,200 $ 28,345

Note 5 - Assets Held for Rent_2

Note 5 - Assets Held for Rent (Details Textual) - USD ($)3 Months Ended
Mar. 31, 2022Mar. 31, 2021
Assets Held for Rent, Depreciation $ 896,000 $ 184,000

Note 5 - Assets Held for Rent -

Note 5 - Assets Held for Rent - Assets Held for Rent (Details) - USD ($) $ in Thousands3 Months Ended12 Months Ended
Mar. 31, 2022Dec. 31, 2021
Shippers placed in service $ 6,032 $ 5,645
Fixed assets held for rent4,686 4,040
Accumulated depreciation(3,070)(2,272)
Net7,648 7,413
Shippers and related components in production2,175 2,396
Total $ 9,823 $ 9,809

Note 6 - Goodwill and Intangi_3

Note 6 - Goodwill and Intangible Assets (Details Textual) - USD ($)3 Months Ended
Mar. 31, 2022Mar. 31, 2021
Amortization of Intangible Assets $ 2,863,000 $ 933,000

Note 6 - Goodwill and Intangi_4

Note 6 - Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands3 Months Ended12 Months Ended
Mar. 31, 2022Dec. 31, 2021
Accumulated Amortization $ (15,176) $ (12,313)
Net Carrying Value81,846
Total intangible assets, gross164,462 164,462
Total intangible assets, net $ 149,286 $ 152,149
Weighted Average [Member]
Weighted Average Useful Life (Year)9 years 7 months 6 days9 years 9 months 18 days
Customer Relationships [Member]
Gross Carrying Value $ 17,516 $ 17,516
Accumulated Amortization(2,376)(1,776)
Net Carrying Value $ 15,140 $ 15,740
Customer Relationships [Member] | Weighted Average [Member]
Weighted Average Useful Life (Year)10 years 1 month 6 days10 years 3 months 18 days
Trade Names [Member]
Gross Carrying Value $ 35,574 $ 35,574
Accumulated Amortization(2,939)(2,306)
Net Carrying Value $ 32,635 $ 33,268
Trade Names [Member] | Weighted Average [Member]
Weighted Average Useful Life (Year)13 years 7 months 6 days13 years 9 months 18 days
Technology-Based Intangible Assets [Member]
Gross Carrying Value $ 41,942 $ 41,942
Accumulated Amortization(9,278)(7,789)
Net Carrying Value $ 32,664 $ 34,153
Technology-Based Intangible Assets [Member] | Weighted Average [Member]
Weighted Average Useful Life (Year)5 years 7 months 6 days5 years 10 months 24 days
Noncompete Agreements [Member]
Gross Carrying Value $ 1,990 $ 1,990
Accumulated Amortization(583)(442)
Net Carrying Value $ 1,407 $ 1,548
Noncompete Agreements [Member] | Weighted Average [Member]
Weighted Average Useful Life (Year)2 years 9 months 18 days3 years
In Process Research and Development [Member]
Gross Carrying Value $ 67,440 [1] $ 67,440
Accumulated Amortization0
Net Carrying Value $ 67,440 [1] $ 67,440
[1]In-process R&D represents the fair value of incomplete research and development that has not yet reached technological feasibility. We will amortize the asset upon technological feasibility.

Note 6 - Goodwill and Intangi_5

Note 6 - Goodwill and Intangible Assets - Future Amortization Expense (Details) $ in ThousandsMar. 31, 2022USD ($)
2022 (9 months remaining) $ 8,558
202310,951
202410,126
20259,748
20269,346
Thereafter33,117
Total $ 81,846

Note 7 - Line of Credit and L_3

Note 7 - Line of Credit and Long-term Debt - Long-term Debt (Details) - USD ($) $ in ThousandsMar. 31, 2022Dec. 31, 2021
Debt, carrying amount $ 6,899 $ 7,246
Less: unamortized debt issuance costs(29)(31)
Total debt6,870 7,215
Less: current portion(557)(862)
Total long-term debt $ 6,313 6,353
The 2019 Term Loan [Member]
Interest rate4.00%
Debt, carrying amount $ 1,750 1,750
The 2018 Term Loan [Member]
Interest rate4.00%
Debt, carrying amount $ 2,896 2,813
Financed Insurance Premium [Member]
Interest rate4.00%
Debt, carrying amount $ 69 373
Freezer Equipment Loan [Member]
Interest rate5.70%
Debt, carrying amount $ 572 612
Manufacturing Equipment Loans [Member]
Interest rate5.70%
Debt, carrying amount $ 333 355
Freezer Installation Loan [Member]
Interest rate6.30%
Debt, carrying amount $ 1,271 1,334
Other Loans [Member]
Debt, carrying amount $ 8 $ 9

Note 7 - Line of Credit and L_4

Note 7 - Line of Credit and Long-term Debt - Maturities of Loans Payable (Details) - USD ($) $ in ThousandsMar. 31, 2022Dec. 31, 2021
2022 (9 months remaining) $ 432
2023813
20242,294
2025543
2026221
Thereafter2,596
Total debt, excluding unamortized debt issuance costs6,899 $ 7,246
Less: unamortized debt issuance costs(29)(31)
Total debt $ 6,870 $ 7,215

Note 8 - Stock-based Compensa_3

Note 8 - Stock-based Compensation (Details Textual) - USD ($)Feb. 24, 2022Feb. 08, 2021Mar. 25, 2020Mar. 31, 2022Mar. 31, 2021Mar. 31, 2022
Share-Based Payment Arrangement, Expense $ 5,399,000 $ 1,505,000
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Expense0 9,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value10,200,000 $ 10,200,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value $ 3,600,000 $ 3,300,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)0 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)3 years 6 months
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total $ 0 0
Performance Shares [Member] | Management Performance Bonus Plan 2017 [Member]
Share-Based Payment Arrangement, Expense $ 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value $ 0 $ 2,900,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)0 0
Restricted Stock [Member]
Share-Based Payment Arrangement, Expense $ 4,800,000 $ 1,400,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total41,400,000 41,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value7,900,000 2,200,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value $ 5,000,000 2,600,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)2 years 10 months 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)301,011
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)165,366
Market-based Restricted Stock [Member]
Share-Based Payment Arrangement, Expense $ 605,000 285,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)349,568
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total $ 7,000,000 7,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value $ 6,700,000 $ 1,300,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)1 year 7 months 6 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)218,280 218,280
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Historical Volatility Rate63.00%68.00%78.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate0.00%0.00%0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate1.50%0.10%0.30%
Share Based Compensation Arrangement By Share Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Period (Year)2 years2 years2 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Aggregate Fair Value $ 6,700,000 $ 1,600,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested $ 5,000,000 $ 10,200,000
Market-based Restricted Stock [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Awards200.00%200.00%200.00%
Market-based Restricted Stock [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Awards0.00%0.00%
Market-based Restricted Stock [Member] | Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)240,428 30,616 109,140
Market-based Restricted Stock Second Issuance [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value $ 1,200,000

Note 8 - Share-based Compensati

Note 8 - Share-based Compensation - Stock Option Activity (Details) - Share-Based Payment Arrangement, Option [Member]3 Months Ended
Mar. 31, 2022$ / sharesshares
Outstanding (in shares) | shares624,531
Outstanding, weighted average exercise price (in dollars per share) | $ / shares $ 2.13
Exercised (in shares) | shares(129,933)
Exercised, weighted average exercise price (in dollars per share) | $ / shares $ 1.98
Outstanding as of March 31, 2022 (in shares) | shares494,598
Outstanding as of March 31, 2022 (in dollars per share) | $ / shares $ 2.17
Stock options exercisable as of March 31, 2022 (in shares) | shares494,598
Options exercisable, weighted average exercise price (in dollars per share) | $ / shares $ 2.17

Note 8 - Share-based Compensa_2

Note 8 - Share-based Compensation - Restricted Stock Activity (Details) - $ / sharesFeb. 24, 2022Mar. 31, 2022
Restricted Stock [Member]
Outstanding (in shares)1,212,783
Outstanding, weighted average exercise price (in dollars per share) $ 37.48
Granted (in shares)301,011
Granted (in dollars per share) $ 26.38
Vested (in shares)(165,366)
Vested (in dollars per share) $ 37.48
Forfeited (in shares)(14,642)
Forfeited (in dollars per share) $ 44.37
Non-vested as of March 31, 2022 (in shares)1,333,786
Non-vested as of March 31, 2022 (in dollars per share) $ 34.90
Market-based Restricted Stock [Member]
Granted (in dollars per share) $ 22.66
Vested (in shares)(218,280)(218,280)
Vested (in dollars per share) $ 10.95
Outstanding (in shares)139,756
Outstanding at beginning of year, grant date fair value (in dollars per share) $ 19.86
Granted (in shares)349,568
Non-vested as of March 31, 2022 (in shares)271,044
Non-vested as of March 31, 2022 (in dollars per share) $ 30.64

Note 8 - Share-based Compensa_3

Note 8 - Share-based Compensation - Stock Compensation Expense (Details) - USD ($) $ in Thousands3 Months Ended
Mar. 31, 2022Mar. 31, 2021
Stock compensation expense $ 5,399 $ 1,505
Research and Development Expense [Member]
Stock compensation expense677 183
Selling and Marketing Expense [Member]
Stock compensation expense705 184
General and Administrative Expense [Member]
Stock compensation expense3,010 979
Cost of Sales [Member]
Stock compensation expense $ 1,007 $ 159

Note 9 - Warrants (Details Text

Note 9 - Warrants (Details Textual) - $ / sharesMar. 25, 2021May 14, 2020Mar. 31, 2022Mar. 31, 2021Dec. 31, 2021Dec. 31, 2020May 31, 2016Mar. 31, 2014
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 0 $ 0 $ 0 $ 4.75
Class of Warrant or Right, Exercised During Period (in shares)0 79,100
Warrants to Purchase Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)6,910,283
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 4.75
Warrants in Connection with WAVI Credit Facility [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)550,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 1.75
WAVI Holding AG and Taurus4757 GmbH Warrants [Member]
Stock Issued During Period, Shares, Cashless Warrant Exercises (in shares)2,747,970
Class of Warrant or Right, Exercised During Period (in shares)3,871,405 79,100
Warrants Exercised [Member]
Stock Issued During Period, Shares, Cashless Warrant Exercises (in shares)70,030
Class of Warrant or Right, Exercised During Period (in shares)79,100

Note 9 - Warrants - Summary of

Note 9 - Warrants - Summary of Warrant Activity (Details) - $ / shares3 Months Ended
Mar. 31, 2022Mar. 31, 2021
Beginning balance (in shares)0 79,100
Beginning balance (in dollars per share) $ 0 $ 4.75
Exercised, number of shares (in shares)0 (79,100)
Exercised, weighted average exercise price (in dollars per share) $ 0 $ 4.75
Ending balance (in shares)0 0
Ending balance (in dollars per share) $ 0 $ 0

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual) - USD ($)3 Months Ended
Mar. 31, 2022Mar. 31, 2021Dec. 31, 2022
Income Tax Expense (Benefit), Total $ (599,000) $ 0
Effective Income Tax Rate Reconciliation, Percent, Total8.00%
Discrete Tax Benefit $ 470,000
Effective Income Tax Rate Reconciliation, Before Discrete Items, Percent5.00%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent21.00%
Forecast [Member]
Deferred Tax Assets, Valuation Allowance $ 6,700,000

Note 11 - Net (Loss) Income P_3

Note 11 - Net (Loss) Income Per Common Share - Calculation of Diluted Shares (Details) - USD ($) $ / shares in Units, $ in Thousands3 Months Ended
Mar. 31, 2022Mar. 31, 2021
Net loss $ (7,066) $ (1,118)
Basic net loss attributable to common stockholders $ (7,066) $ (1,118)
Basic and diluted weighted averge shares outstanding (in shares)42,014,055 33,236,818
Basic and diluted earnings per share attributable to common stockholders (in dollars per share) $ (0.17) $ (0.03)

Note 11 - Net (Loss) Income Com

Note 11 - Net (Loss) Income Common Share - Anti-dilutive Securities Excluded From Computation (Details) - shares3 Months Ended
Mar. 31, 2022Mar. 31, 2021
Anti-dilutive securities (in shares)2,094,863 2,208,711
Share-based Payment Arrangement, Option and Restricted Stock Awards [Member]
Anti-dilutive securities (in shares)2,094,863 2,134,884
Warrant [Member]
Anti-dilutive securities (in shares)0 73,827

Note 13 - Revenue (Details Text

Note 13 - Revenue (Details Textual)3 Months Ended
Mar. 31, 2022USD ($)
Deferred Revenue, Revenue Recognized $ 74,000

Note 13 - Revenue - Revenues by

Note 13 - Revenue - Revenues by Product Line (Details) - USD ($) $ in Thousands3 Months Ended
Mar. 31, 2022Mar. 31, 2021
Total revenue $ 36,220 $ 16,847
Product, Freezer and Thaw [Member]
Total revenue15,335 4,848
Product, Cell Processing [Member]
Total revenue14,899 8,928
Product, Storage and Cold Chain Services [Member]
Total revenue154 0
Service, Storage and Cold Chain Services [Member]
Total revenue3,090 2,204
Rental, Storage and Cold Chain Services [Member]
Total revenue $ 2,742 $ 867

Note 13 - Revenue - Summary of

Note 13 - Revenue - Summary of Remaining Performance Obligations (Details) $ in ThousandsMar. 31, 2022USD ($)
Rental Revenue [Member]
Service revenue, expected to be recognized in the future $ 11,703
Service Revenue [Member]
Service revenue, expected to be recognized in the future $ 205

Note 13 - Revenue - Summary o_2

Note 13 - Revenue - Summary of Remaining Performance Obligations 2 (Details) $ in ThousandsMar. 31, 2022USD ($)
Rental Revenue [Member]
Service revenue, expected to be recognized in the future $ 11,703
Rental Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01
Service revenue, expected to be recognized in the future $ 7,068
Service revenue, expected to be recognized in the future, period (Year)9 months
Rental Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Service revenue, expected to be recognized in the future $ 3,735
Service revenue, expected to be recognized in the future, period (Year)1 year
Rental Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Service revenue, expected to be recognized in the future $ 900
Service revenue, expected to be recognized in the future, period (Year)1 year
Service Revenue [Member]
Service revenue, expected to be recognized in the future $ 205
Service Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01
Service revenue, expected to be recognized in the future $ 79
Service revenue, expected to be recognized in the future, period (Year)9 months
Service Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Service revenue, expected to be recognized in the future $ 116
Service revenue, expected to be recognized in the future, period (Year)1 year
Service Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Service revenue, expected to be recognized in the future $ 10
Service revenue, expected to be recognized in the future, period (Year)1 year

Note 14 - Leases (Details Textu

Note 14 - Leases (Details Textual)Mar. 31, 2022
Maximum [Member] | Real Estate Lease[Member]
Lessee, Operating Lease, Remaining Lease Term (Year)10 years
Maximum [Member] | Lease Extensions [Member]
Lessee, Operating Lease, Term of Contract (Year)5 years
Minimum [Member] | Real Estate Lease[Member]
Lessee, Operating Lease, Remaining Lease Term (Year)1 year
Minimum [Member] | Lease Extensions [Member]
Lessee, Operating Lease, Term of Contract (Year)1 year

Note 14 - Leases - Lease Term a

Note 14 - Leases - Lease Term and Discount Rate (Details)Mar. 31, 2022Dec. 31, 2021
Weighted average discount rate - operating leases3.80%3.80%
Weighted average discount rate - finance leases6.10%6.10%
Weighted average remaining lease term in years - operating leases (Year)7 years 7 months 6 days7 years 9 months 18 days
Weighted average remaining lease term in years - finance leases (Year)2 years 8 months 12 days3 years

Note 14 - Leases - Components o

Note 14 - Leases - Components of Lease Expense (Details) - USD ($) $ in Thousands3 Months Ended
Mar. 31, 2022Mar. 31, 2021
Operating lease costs $ 913 $ 460
Short-term lease costs565 137
Total operating lease costs1,478 597
Variable lease costs305 128
Total lease costs $ 1,783 $ 725

Note 14 - Leases - Maturities o

Note 14 - Leases - Maturities of Lease Liabilities (Details) $ in ThousandsMar. 31, 2022USD ($)
2022 (9 months remaining), operating leases $ 2,626
2022 (9 months remaining), finance leases129
2023, operating leases3,230
2023, finance leases171
2024, operating leases2,950
2024, finance leases101
2025, operating leases2,485
2025, finance leases37
2026, operating leases2,005
2026, finance leases2
Thereafter, operating leases8,363
Thereafter, finance leases0
Total operating lease payments21,659
Total financing lease payments, finance leases440
Less: operating lease interest(2,947)
Less: financing lease interest(36)
Total present value of operating lease liabilities18,712
Total present value of financing lease liabilities $ 404

Note 15 - Consolidated Balanc_3

Note 15 - Consolidated Balance Sheet Detail (Details Textual) - USD ($)3 Months Ended
Mar. 31, 2022Mar. 31, 2021
Depreciation, Total $ 757,000 $ 575,000

Note 15 - Consolidated Balanc_4

Note 15 - Consolidated Balance Sheet Detail - Property and Equipment (Details) - USD ($) $ in ThousandsMar. 31, 2022Dec. 31, 2021
Property and equipment $ 25,393 $ 24,398
Less: Accumulated depreciation(7,134)(6,741)
Net property and equipment18,259 17,657
Leasehold Improvements [Member]
Property and equipment3,949 3,840
Furniture and Computer Equipment [Member]
Property and equipment1,819 1,861
Manufacturing Facility [Member]
Property and equipment16,807 16,675
Construction in Progress [Member]
Property and equipment $ 2,818 $ 2,022

Note 15 - Consolidated Balanc_5

Note 15 - Consolidated Balance Sheet Detail - Accrued Liabilities and Other Current Liabilities (Details) - USD ($) $ in ThousandsMar. 31, 2022Dec. 31, 2021
Accrued compensation $ 4,535 $ 4,351
Accrued expenses1,372 1,656
Deferred revenue, current895 814
Accrued taxes33 27
Other131 294
Total accrued expenses and other current liabilities $ 6,966 $ 7,142

Note 15 - Consolidated Balanc_6

Note 15 - Consolidated Balance Sheet Detail - Warranty Reserve Liability (Details) - USD ($) $ in Thousands3 Months Ended
Mar. 31, 2022Mar. 31, 2021
Beginning balance $ 9,398 $ 212
Provision for warranties894 11
Settlements of warranty claims(1,116)(22)
Ending Balance $ 9,176 $ 201

Note 16 - Employee Benefit Pl_2

Note 16 - Employee Benefit Plan (Details Textual) - Defined Contribution Plan, 401 K [Member] - Pension Plan [Member] - USD ($)3 Months Ended
Mar. 31, 2022Mar. 31, 2021
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay100.00%
Defined Contribution Plan, Employer Discretionary Contribution Amount $ 226,000 $ 135,000